An observational study in 2019-nCoV, sponsored by Chongqing Medical University. Withdrawn at 1 site in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2020-03-17.
Sponsored by Chongqing Medical University · Observational
There are currently no clinical studies reporting clinical characteristics difference between the hypertension patients with and without ACEI treatment when suffered with novel coronavirus infection in China.
At present, the outbreak of the new coronavirus (2019-nCoV) infection in Wuhan and Hubei provinces has attracted great attention from the medical community across the country. Both 2019-nCoV and SARS viruses are coronaviruses, and they have a large homology.
Published laboratory studies have suggested that SARS virus infection and its lung injury are related to angiotensin-converting enzyme 2 (ACE2) in lung tissue. And ACE and ACE2 in the renin-angiotensin system (RAS) are vital central links to maintain hemodynamic stability and normal heart and kidney function in vivo.
A large amount of evidence-based medical evidence shows that ACE inhibitors are the basic therapeutic drugs for maintaining hypertension, reducing the risk of cardiovascular, cerebrovascular, and renal adverse events, improving quality of life, and prolonging life in patients with hypertension. Recent experimental studies suggest that treatment with ACE inhibitors can significantly reduce pulmonary inflammation and cytokine release caused by coronavirus infection.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
Browse Hypertension studies →Chongqing Medical University is the lead sponsor of 75 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
the hypertension patients with and without ACEI treatment when suffered with novel coronavirus infection in China
Exclusion Criteria:
hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China
Occupancy rate in the intensive care unit (ICU)
The percentage of patients admitted to the ICU at any time during the 28 days of onset COVID-19.
Time frame: up to 28 days
Mechanical Ventilation
The number of patients requiring mechanical ventilation.
Time frame: up to 28 days
Death
The number of patients who died of 2019-nCoV infection.
Time frame: up to 28 days
All cause mortality
The number of died 2019-nCoV infected patients from any cause.
Time frame: up to 28 days
Time from onset of symptoms to main outcome and its components
Time from onset of symptoms to admitted to the ICU, requiring mechanical ventilation, and death.
Time frame: up to 28 days
Time to Clinical Recovery
Time to Clinical Recovery
Time frame: up to 28 days
This study is withdrawn, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chongqing Medical University